Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database.
about
Sildenafil citrate for erectile dysfunction in patients with multiple sclerosisSildenafil citrate for erectile dysfunction in patients with multiple sclerosisPharmacogenetics of erectile dysfunction: navigating into uncharted watersAcute onset of bilateral visual loss during sildenafil therapy in a young infant with congenital heart diseaseSildenafil increases muscle protein synthesis and reduces muscle fatigue.Enhancing cognition before clinical symptoms of dementia.The future is today: emerging drugs for the treatment of erectile dysfunctionUrologic medications and ophthalmologic side effects: a review.Prolonged, longstanding, ultra-high-dose abuse of sildenafil.The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease.Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Pulmonary Hypertension.Improvement in erection hardness and intercourse success with first dose of sildenafil citrate 100 mgPhosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality.Erectile dysfunction as a complication of heart failure.Investigational noncardiovascular uses of phosphodiesterase-5 inhibitors.ADMET considerations for phosphodiesterase-5 inhibitors.Erectile dysfunction in the cardiovascular patient.Pharmacologic therapy for erectile dysfunction and its interaction with the cardiovascular system.The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction.Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors.Serum testosterone, testosterone replacement therapy and all-cause mortality in men with type 2 diabetes: retrospective consideration of the impact of PDE5 inhibitors and statins.Inhaled sildenafil nanocomposites: lung accumulation and pulmonary pharmacokinetics.Sequential, non-arteritic anterior ischemic optic neuropathy in patients taking sildenafil: a report of ten cases.An open-label, long-term evaluation of the safety, efficacy and tolerability of avanafil in male patients with mild to severe erectile dysfunction.Do men with mild erectile dysfunction have the same risk factors as the general erectile dysfunction clinical trial population?Effect of Linear Low-Intensity Extracorporeal Shockwave Therapy for Erectile Dysfunction-12-Month Follow-Up of a Randomized, Double-Blinded, Sham-Controlled Study.Quality of erections by age group in men with erectile dysfunction.A Non-Fatal Self-Poisoning Attempt with Sildenafil.An unheard benefit of phosphodiesterase inhibition.Utero-placental perfusion Doppler indices in growth restricted fetuses: effect of sildenafil citrate.Randomised clinical trial: a leucine-metformin-sildenafil combination (NS-0200) vs placebo in patients with non-alcoholic fatty liver disease.Erectile dysfunctionPrevalence and detection rate of underlying disease in men with erectile dysfunction receiving phosphodiesterase type 5 inhibitors in the United Kingdom: a retrospective database study
P2860
Q24200422-2C7D7D5F-50B2-44B9-9F9F-3AC9E6A54991Q24235610-9F0FD848-36C2-4136-A92D-2828BFAAB711Q28249515-372CCB19-F884-4278-9396-52C941A89F3BQ33744291-1586E75C-0782-48B2-8196-E6C5FCE7226CQ33827719-FD33F408-E194-4383-BDE2-5D0028422169Q34708103-A7CF5D12-A4BD-488A-88ED-30832A9CEE4BQ35186022-BEBAEB30-FEB9-41D3-8616-D753A1F9E3DCQ35788323-23D78CDD-23AD-415F-A84B-4D0935D25510Q36216821-6D76D809-3954-40A3-B1AC-803DAF7866DEQ36399555-9B84760D-425C-411D-BB4F-0408E020E1A5Q36763080-A9ACFC53-1639-44E7-916D-92B7142A6B98Q37332804-9BEAEF51-CFDB-4C3E-8B80-6737A6EABC53Q37398972-DE9AA496-9552-4E9E-842E-AC5F921D964EQ37776171-E25AA9F1-9C78-4C63-BA7B-F89DBC78B2DCQ37903037-ED5412E8-AF31-468B-A43A-E266952ED21FQ38024409-4E13CE24-EEF7-4300-9223-E910D5F7919EQ38101543-34F648AC-B78F-43A9-AB7D-5C7F54754147Q38166600-F3EE7CBA-10D4-41E8-9070-F1BA9EB95238Q38692296-F32D2BDF-7C3B-439A-805C-181A28F3D9BEQ38815890-DB0B5C43-0927-425F-A0F6-BDD3A98062EFQ39967508-845BC41F-2C60-4A92-95AA-1CD4D55568E8Q41275250-308CFB3D-245D-47B6-8AD8-828C16E95F09Q41860984-59891683-546A-4D0A-985B-F22C06FC6B23Q42693466-1167436D-D7B3-4ADE-B11A-3A8882B588AFQ44921724-63FEBAB1-5A22-4762-BE3B-BE45399BF9F9Q47252153-0F2AB348-B8EA-404C-85E1-C2AE2DFBAE08Q48003786-F116812D-64B0-4C24-B610-386F8FCA43A2Q48078813-6DDD60E8-CB68-4AA8-A77A-DF0F5AFE2DD5Q50431585-D0217A0C-74DD-474A-BD34-0CBB45A11C6FQ53734639-AAB09254-54C0-4CAB-882A-578650A3A09EQ54528195-C702464D-3943-448D-848A-FE38B0943394Q56966121-C345743A-70DE-482F-9198-674DAE0D48F4Q57644637-B4DB105A-C5F0-4B0A-9B49-9E7324875F21
P2860
Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Safety of sildenafil citrate: ...... postmarketing safety database.
@ast
Safety of sildenafil citrate: ...... postmarketing safety database.
@en
type
label
Safety of sildenafil citrate: ...... postmarketing safety database.
@ast
Safety of sildenafil citrate: ...... postmarketing safety database.
@en
prefLabel
Safety of sildenafil citrate: ...... postmarketing safety database.
@ast
Safety of sildenafil citrate: ...... postmarketing safety database.
@en
P2093
P2860
P921
P1476
Safety of sildenafil citrate: ...... postmarketing safety database.
@en
P2093
A Martin-Morales
F Giuliano
F Montorsi
P Raillard
P2860
P304
P356
10.1111/J.1742-1241.2009.02254.X
P5008
P577
2009-11-09T00:00:00Z
2010-01-01T00:00:00Z